Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00331188 · ClinicalTrials.gov registry record · Phase 3

Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding

A Phase 3 study of Portal Hypertension and Esophageal Varices, sponsored by Debiovision.

Completed
Registry status
Phase 3
Development phase
70
Enrollment target
19
Study locations

NCT00331188 is a Phase 3 study of Portal Hypertension and Esophageal Varices that has completed, run by Debiovision. The registered enrollment target is 70 participants, below the 201-participant average among 9 other Portal Hypertension trials with a reported enrollment target (65% lower). The trial reports 19 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00331188, a Phase 3 study of Portal Hypertension and Esophageal Varices, has completed, sponsored by Debiovision.

COMPLETED
Registry status
Phase 3
Development phase
70 participants
Enrollment target
19
Study locations

Study Summary

The main objective of this study is to determine the efficacy of early administration of Sanvar® in combination with endoscopic treatment for the control of acute variceal bleeding.

Interventions

  • DRUG Sanvar® (vapreotide)

Study Locations (19)

Alabama

  • UAB Liver Center - Birmingham
  • Alabama Liver & Digestive Specialists - Montgomery

New York

  • Weill Medical College of Cornell University - New York
  • Columbia University Medical Center - New York

Arizona

  • Mayo Clinic - Scottsdale

California

  • University of California at San Diego - San Diego

Colorado

  • University of Colorado Health Sciences Center - Denver

Connecticut

  • Yale University School of Medicine - New Haven

Florida

  • Mayo Clinic - Jacksonville

Illinois

  • Northwestern University, The Feinberg School of Medicine - Chicago

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2006-05
Est. Completion 2008-07
Phase Phase 3

Sponsor

Debiovision

1 total trials

What the Registry Record Tells You About NCT00331188

The ClinicalTrials.gov registry entry for NCT00331188 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 9 other Portal Hypertension trials with a reported enrollment target (65% lower). The listed sponsor is Debiovision, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Portal Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Sanvar® (vapreotide) is the first listed.

NCT00331188 reports 19 study locations spanning 17 distinct geographic areas - top geographies include Alabama, New York, Arizona.

Frequently Asked Questions

What is clinical trial NCT00331188 about?

NCT00331188 is a clinical study titled "Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding". The main objective of this study is to determine the efficacy of early administration of Sanvar® in combination with endoscopic treatment for the control of acute variceal bleeding.

What is the current status of trial NCT00331188?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 70 participants. The study started on 2006-05. Estimated completion is 2008-07.

What conditions does trial NCT00331188 study?

This clinical trial studies the following conditions: Portal Hypertension, Esophageal Varices, Gastric Varices, Esophageal Bleeding.

What interventions are being tested in trial NCT00331188?

The interventions under investigation include: Sanvar® (vapreotide) (DRUG).

Who is sponsoring clinical trial NCT00331188?

This trial is sponsored by Debiovision, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00331188 being conducted?

This trial has 19 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Portal Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.